The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

A quarter of BP investors have voted against the re-election of outgoing chair Helge Lund in the biggest protest against a FTSE 100 director for five years.

Novo Nordisk has promoted Rishang Deoras to Global Director - Diabetes Commercial Unit.Deoras shared the news in a LinkedIn ...

A daily pill developed by Eli Lilly significantly lowered blood sugar levels and led to weight loss in people with Type 2 ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company’s obesity ...